OCULAR HSV--LATENCY, REACTIVATION, AND RECURRENCE
眼部单纯疱疹病毒——潜伏期、再激活和复发
基本信息
- 批准号:2019527
- 负责人:
- 金额:$ 19.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1985
- 资助国家:美国
- 起止时间:1985-07-01 至 2002-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The PI proposes to elucidate the pharmacological and molecular
mechanisms that underlie reactivation of latent HSV from trigeminal
ganglia (TG). A variety of studies involving HSV DNA and the RNAs
designated as latency-associated transcripts (LAT) will be done using
animal models of HSV reactivation.
The specific aims are 1) to determine the relationship between specific
sequence elements in the LAT promoter and the mechanisms that
govern the ability to undergo in vivo adrenergic reactivation; 2) to
detect and quantitate HSV transcripts in he TG from animals
harboring latent viruses that exhibit different phenotypes and
genotypes before and after adrenergic reactivation; and 3) to
characterize the pharmacological and molecular mechanisms involved
in propranolol inhibition of in vivo reactivation in animals harboring
latent viruses that exhibit different phenotypes and genotypes. The
methodology includes iontophoresis of epinephrine and hyperthermia
to induce HSV reactivation, slit-lamp examination to detect
spontaneous corneal epithelial lesions, sequence analysis of LAT
regions of HSV DNA, detection of HSV DNA methylation, and RT-
PCR to quantitate HSV RNAs. The long-term goal is to provide
insights into HSV pathogenesis that could result in the development of
therapeutic strategies to block neuronal HSV reactivation and the
morbidity caused by repeated episodes of herpetic disease.
PI提议阐明药理和分子
三叉神经的潜在HSV重新激活的机制
神经节(TG)。 涉及HSV DNA和RNA的各种研究
指定为与延迟相关的成绩单(LAT)的指定
HSV重新激活的动物模型。
具体目的是1)确定特定之间的关系
LAT启动子中的序列元素和机制
控制体内肾上腺素能重新激活的能力; 2)到
从动物中检测并定量HSV转录本
具有表现出不同表型的潜在病毒和
肾上腺素能重新激活之前和之后的基因型;和3)到
表征涉及的药理和分子机制
在抑制携带动物体内重新激活的普萘洛尔
表现出不同表型和基因型的潜在病毒。 这
方法包括肾上腺素和高温的离子噬菌体
为了诱导HSV重新激活,请检查扫描灯检查以检测
自发角膜上皮病变,LAT的序列分析
HSV DNA的区域,HSV DNA甲基化的检测和RT-
PCR定量HSV RNA。 长期目标是提供
对HSV发病机理的见解,这可能导致
阻止神经元HSV重新激活的治疗策略和
由疱疹性疾病反复发作引起的发病率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
JAMES M HILL的其他基金
Aging, Herpesviruses, and Alzheimer's Disease
衰老、疱疹病毒和阿尔茨海默病
- 批准号:69482536948253
- 财政年份:2004
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Aging, Herpesviruses, and Alzheimer's Disease
衰老、疱疹病毒和阿尔茨海默病
- 批准号:71101407110140
- 财政年份:2004
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Aging, Herpesviruses, and Alzheimer's Disease
衰老、疱疹病毒和阿尔茨海默病
- 批准号:68265626826562
- 财政年份:2004
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Aging, Herpesviruses, and Alzheimer's Disease
衰老、疱疹病毒和阿尔茨海默病
- 批准号:72841997284199
- 财政年份:2004
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
CORE--CULTURE (VIRUSES, BACTERIA, PLASMIDS, AND CELLS)
核心——培养(病毒、细菌、质粒和细胞)
- 批准号:65804056580405
- 财政年份:2002
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
CORE--CULTURE (VIRUSES, BACTERIA, PLASMIDS, AND CELLS)
核心——培养(病毒、细菌、质粒和细胞)
- 批准号:63015986301598
- 财政年份:2000
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
CORE--CULTURE (VIRUSES, BACTERIA, PLASMIDS, AND CELLS)
核心——培养(病毒、细菌、质粒和细胞)
- 批准号:61069116106911
- 财政年份:1999
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
相似海外基金
Development of AAV-AXN-007 gene therapy to treat glaucoma.
开发 AAV-AXN-007 基因疗法来治疗青光眼。
- 批准号:1054723110547231
- 财政年份:2022
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Elucidating Central Neural Mechanisms in an Apnea Model
阐明呼吸暂停模型中的中枢神经机制
- 批准号:1039646510396465
- 财政年份:2021
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
在散发性脑淀粉样血管病的非人灵长类动物模型中通过 CpG ODN 刺激先天免疫
- 批准号:1016187010161870
- 财政年份:2017
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Innate Immunity Stimulation via CpG ODN in a Non-Human Primate Model of Sporadic Cerebral Amyloid Angiopathy
在散发性脑淀粉样血管病的非人灵长类动物模型中通过 CpG ODN 刺激先天免疫
- 批准号:93679189367918
- 财政年份:2017
- 资助金额:$ 19.7万$ 19.7万
- 项目类别:
Fifth International Conference on Primate Genomics
第五届国际灵长类基因组学会议
- 批准号:83229798322979
- 财政年份:2012
- 资助金额:$ 19.7万$ 19.7万
- 项目类别: